Conformal radiotherapy of the dominant liver metastasis: A viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 6, 2006, Pages 562-567

  Krishnan, Sunil ^a   Lin, Edward H ^a   Gunn, G Brandon ^a   Chandra, Anshu ^a   Beddar, A Sam ^a   Briere, Tina M ^a   Das, Prajnan ^a   Delclos, Marc E ^a   Janjan, Nora A ^a   Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Conformal radiotherapy; Dominant; Liver metastases

Indexed keywords

CAPECITABINE; CELECOXIB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; UFT;

ACUTE DIARRHEA; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; MALE; MEDICAL RECORD; NAUSEA; NEUTROPENIA; PATIENT SAFETY; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33845474086     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000236210.41199.91     Document Type: Conference Paper

References (29)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946.
3. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-450.
4. Curley SA, Izzo F, Abdalla E, et al. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev. 2004;23:165-182.
5. Thirion P, Wolmark N, Haddad E, et al. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol. 1999;10:1317-1320.
6. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
7. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
11. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
12. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059-2069.
13. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
14. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
15. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
17. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
18. Whisenant J, Venook A. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. Oncology (Huntingt). 2004;18:762-773.
19. Sullivan KL. Hepatic artery chemoembolization. Semin Oncol. 2002;29:145-151.
20. Subar DA, Sheen AJ, Sherlock DJ. Cryoablation for liver tumors: is there clinical utility? Med Gen Med. 2003;5:19.
21. Donckier V, Van Laethem JL, Ickx B, et al. Local ablative treatments for liver metastases: the current situation. Acta Chir Belg. 2003;103:452-457.
22. Lawrence TS, Dworzanin LM, Walker-Andrews SC, et al. Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys. 1991;20:555-561.
23. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810-821.
24. Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol. 1996;14:722-728.
25. Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861-870.
26. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164-170.
27. Wulf J, Hadinger U, Oppitz U, et al. Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. Radiother Oncol. 2003;66:141-150.
28. Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol. 2002;29:152-159.
29. Kaplan E, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.